| Date | Title | Description |
| 30.08.2024 | Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons | Company announcement – No. 43 / 2024
Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons
Copenhagen, Denmark, August 30, 2024 – Zealand P... |
| 08.07.2024 | Danish pole position among best Nordic life science stocks in H1 | Danish pole position among best Nordic life science stocks in H1
Mon, Jul 08, 2024 07:45 CET Report this content
The first six months of 2024 have passed and it is time to swap the ergonomically designed office chair for a sunbed At BioStoc... |
| 25.06.2024 | Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion | Company announcement – No. 33 / 2024
Zealand Pharma launches equity offering of new shares raising gross proceeds of approximately USD 900 million / DKK 6.257 billion
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN WHOLE OR IN PART IN OR IN... |
| 20.06.2024 | Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide | Company announcement – No. 32 / 2024
Zealand Pharma announces positive topline results from the Phase 1b 16-week multiple ascending dose clinical trial with long-acting amylin analog petrelintide
Body weight reductions of up to a mean of 8.... |
| 29.05.2024 | Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024 | Press release – No. 5 / 2024
Zealand Pharma to participate in upcoming healthcare investor conferences in June 2024
Copenhagen, Denmark, May 29, 2024 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on... |
| 04.04.2024 | The CEO of a weight-loss ETF that's crushing the S&P 500 since launching in November shares 4 stocks he sees with over 100% upside in the next 12 months | Markets The CEO of a weight-loss ETF that's crushing the S&P 500 since launching in November shares 4 stocks he sees with over 100% upside in the next 12 months
William Edwards
2024-04-04T14:09:13Z
Share icon An curved arrow pointing ri... |
| 17.03.2024 | Weight loss drugs like Ozempic and Wegovy are fattening up Denmark's economy and helped it dodge a recession last year | Economy Weight loss drugs like Ozempic and Wegovy are fattening up Denmark's economy and helped it dodge a recession last year
George Glover
2024-03-17T08:31:02Z
Share icon An curved arrow pointing right.
Share
Facebook Icon The letter F.
F... |
| 13.03.2024 | New Employee Elected Directors to the Board of Zealand Pharma A/S | - |
| 08.03.2024 | Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons | - |
| 05.03.2024 | Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons | - |
| 05.03.2024 | Zealand Pharma Increases its Share Capital as a Consequence of Exercise of Employee Warrants | - |
| 22.12.2023 | Zealand Pharma enters into EUR 90 million finance agreement with the European Investment Bank | - |
| 18.09.2023 | Is Denmark Setting the Global Standard in Peptide-Based Biopharmaceutical Innovation? | Key Takeaways:
Zealand Pharma, based in Denmark, is a leader in peptide-based biopharmaceutical innovation.
Through a variety of partnerships and proprietary developments, Zealand Pharma has made significant strides in developing peptide-ba... |
| 17.08.2023 | Zealand Pharma Announces Financial Results for the First Half of 2023 | Company announcement - No. 28 / 2023
Zealand Pharma Announces Financial Results for the First Half of 2023
Strong progress across R&D pipeline and significant strengthening of the balance sheet
Boehringer Ingelheim to move into Phase 3 ... |
| 30.06.2023 | Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism | /EIN News/ -- Press release – No. 8 / 2023
Zealand Pharma submits New Drug Application to US FDA for dasiglucagon in congenital hyperinsulinism
Copenhagen, Denmark, June 30, 2023 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a bio... |
| 11.10.2022 | Zealand Pharma major shareholder announcement: Polar Capital | Company announcement – No. 47 / 2022
Zealand Pharma major shareholder announcement: Polar Capital
Copenhagen, Denmark and Boston, MA, 11 October 2022 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based ... |
| 10.10.2022 | Zealand Pharma major shareholder announcement: Van Herk Investments | Company announcement – No. 46 / 2022
Zealand Pharma major shareholder announcement: Van Herk Investments
Copenhagen, Denmark and Boston, MA, 10 October 2022 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen... |
| 10.10.2022 | Zealand Pharma major shareholder announcement: Van Herk Investments | /EIN News/ -- Company announcement – No. 46 / 2022
Zealand Pharma major shareholder announcement: Van Herk Investments
Copenhagen, Denmark and Boston, MA, 10 October 2022 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78)... |
| 13.09.2022 | Zealand Pharma grants warrants to employees in Denmark | Company announcement – No. 40 / 2022
Zealand Pharma grants warrants to employees in Denmark
Copenhagen, DK and Boston, MA, September 13, 2022 – Zealand Pharma A/S (“Zealand”) (Nasdaq: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-based biotechn... |
| 30.06.2022 | Total number of shares and voting rights in Zealand Pharma at June 30, 2022 | Company announcement – No. 30 / 2022
Total number of shares and voting rights in Zealand Pharma at June 30, 2022
Copenhagen, DK and Boston, MA, June 30, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhage... |
| 10.06.2022 | Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022 | Company announcement – No. 28 / 2022
Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022
Copenhagen, DK and Boston, MA, 10 June 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen... |
| 19.05.2022 | Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI) | Company announcement – No. 22 / 2022
Zealand Pharma Announces Positive Results from Phase 3 Trial of Dasiglucagon in Pediatric Patients with Congenital Hyperinsulinism (CHI) Dasiglucagon met the primary endpoint with statistical significanc... |
| 10.05.2022 | Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022 | Company announcement – No. 17 / 2022
Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2022
Copenhagen, DK and Boston, MA, May 10 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copenhagen-... |
| 07.04.2022 | Correction: Zealand Pharma major shareholder announcement: Polar Capital LLP, April 7 2022 | Company announcement – No. 13 / 2022
CORRECTION: Zealand Pharma major shareholder announcement: Polar Capital LLP, April 7 2022
Copenhagen, DK and Boston, MA, April 7, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 7... |
| 07.04.2022 | Zealand Pharma major shareholder announcement: The Capital Group Companies, April 7 2022 | Company announcement – No. 13 / 2022
Zealand Pharma major shareholder announcement: The Capital Group Companies, April 7 2022
Copenhagen, DK and Boston, MA, April 7, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78)... |
| 30.03.2022 | Zealand Pharma Appoints New Chief Executive Officer, Refocuses Strategy to Prioritize Research & Development and Streamlines Operations | Company announcement – No. 10 / 2022
Zealand Pharma Appoints New Chief Executive Officer, Refocuses Strategy to Prioritize Research & Development and Streamlines Operations Dr. Adam Steensberg assumes the position of Chief Executive Off... |
| 11.03.2022 | Correction: Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data for Glepaglutide and Dasiglucagon Programs Expected in 2022. | Company announcement – No. 9 / 2022
Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data for Glepaglutide and Dasiglucagon Programs Expected in 2022.
Full Year Results for 2021
Copenhagen, ... |
| 10.03.2022 | Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data for Glepaglutide and Dasiglucagon Programs Expected in 2022. | Company announcement – No. 7 / 2022
Zealand Pharma: Significant Advancement of Clinical Pipeline and Building Commercial Momentum. Key Data for Glepaglutide and Dasiglucagon Programs Expected in 2022.
Full Year Results for 2021
Copenhagen, ... |
| 25.02.2022 | Zealand Pharma major shareholder announcement: The Capital Group Companies, 2022 | Company announcement – No. 5 / 2022
Zealand Pharma major shareholder announcement: The Capital Group Companies, 2022
Copenhagen, DK and Boston, MA, February 25, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a C... |
| 20.01.2022 | Zealand Pharma Completes Enrollment in EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome | Company announcement – No. 3 / 2022
Zealand Pharma Completes Enrollment in EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome Full trial results of EASE-SBS 1 expected in the third quarter of 2022Pending p... |
| 19.01.2022 | Zealand Pharma major shareholder announcement: The Capital Group Companies, January 2022 | Company announcement – No. 2 / 2021
Zealand Pharma major shareholder announcement: The Capital Group Companies, January 2022
Copenhagen, DK and Boston, MA, January 19, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 7... |
| 19.01.2022 | Zealand Pharma major shareholder announcement: The Capital Group Companies, January 2022 | Company announcement – No. 2 / 2021
Zealand Pharma major shareholder announcement: The Capital Group Companies, January 2022
Copenhagen, DK and Boston, MA, January 19, 2022 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 7... |
| 30.12.2021 | Total number of shares and voting rights in Zealand Pharma at December 30, 2021 | Company announcement – No. 78 / 2021
Total number of shares and voting rights in Zealand Pharma at December 30, 2021
Copenhagen, DK and Boston, MA, December 30, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a C... |
| 24.12.2021 | Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021 | Company announcement – No. 77 / 2021
Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021
Copenhagen, DK and Boston, MA, December 24, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a... |
| 24.12.2021 | Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021 | Company announcement – No. 77 / 2021
Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021
Copenhagen, DK and Boston, MA, December 24, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a... |
| 16.12.2021 | Zealand Pharma A/S : Announces Seven-Year, $200 Million Financing Agreement with Oberland Capital - Form 6-K | Zealand Pharma Announces Seven-Year, $200 Million Financing Agreement with Oberland Capital
· Agreement includes an upfront payment of $100 million in exchange for a 7-year, interest-only secured note
· The non-dilutive debt facility will s... |
| 16.12.2021 | Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome | Company announcement – No. 76 / 2021
Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome
Interim analysis for the trial exp... |
| 16.12.2021 | Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome | Company announcement – No. 76 / 2021
Zealand Pharma Announces Enrollment of Last Patient Needed for Interim Analysis of EASE-SBS 1 Phase 3 Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome
Interim analysis for the trial exp... |
| 14.12.2021 | Zealand Pharma Announces Seven-Year, $200 Million Financing Agreement with Oberland Capital | Company announcement – No. 75 / 2021
Zealand Pharma Announces Seven-Year, $200 Million Financing Agreement with Oberland Capital
Agreement includes an upfront payment of $100 million in exchange for a 7-year, interest-only secured note
The ... |
| 14.12.2021 | Zealand Pharma Announces Seven-Year, $200 Million Financing Agreement with Oberland Capital | Company announcement – No. 75 / 2021
Zealand Pharma Announces Seven-Year, $200 Million Financing Agreement with Oberland Capital
Agreement includes an upfront payment of $100 million in exchange for a 7-year, interest-only secured note
The ... |
| 10.12.2021 | Zealand Pharma increases its share capital as a consequence of exercise of employee warrants | Company announcement – No. 74 / 2021
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
Copenhagen, DK and Boston, MA, U.S. December 10, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), ... |
| 10.12.2021 | Zealand Pharma increases its share capital as a consequence of exercise of employee warrants | Company announcement – No. 74 / 2021
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
Copenhagen, DK and Boston, MA, U.S. December 10, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), ... |
| 30.11.2021 | Total number of shares and voting rights in Zealand Pharma at November 30, 2021 | Company announcement – No. 72 / 2021
Total number of shares and voting rights in Zealand Pharma at November 30, 2021
Copenhagen, DK and Boston, MA, November 30, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a C... |
| 30.11.2021 | Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021 | Company announcement – No. 73 / 2021
Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021
Copenhagen, DK and Boston, MA, November 30, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a ... |
| 30.11.2021 | Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021 | Company announcement – No. 73 / 2021
Zealand Pharma major shareholder announcement: The Capital Group Companies, 2021
Copenhagen, DK and Boston, MA, November 30, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a ... |
| 29.11.2021 | Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2021 | Company announcement – No. 71 / 2021
Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2021
Copenhagen, DK and Boston, MA, November 29, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copen... |
| 29.11.2021 | Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2021 | Company announcement – No. 71 / 2021
Zealand Pharma major shareholder announcement: Credit Suisse Group AG, 2021
Copenhagen, DK and Boston, MA, November 29, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) (CVR-no. 20 04 50 78), a Copen... |
| 23.11.2021 | Zealand Pharma A/S : announces successful outcome of Phase 1b clinical trial with GLP1-GLP2 dual receptor agonist, dapiglutide - Form 6-K | Zealand Pharma announces successful outcome of Phase 1b clinical trial with GLP1-GLP2 dual receptor agonist, dapiglutide
Company announcement - No. 70 / 2021
• Dapiglutide was assessed to be safe and well tolerated following 4 weeks of dosi... |
| 20.11.2021 | Zealand Pharma A/S : Company announcement – No. 69/ 2021 Company announcement – No. 69 / 2021 - Form 6-K | Company announcement - No. 69/ 2021
Company announcement - No. 69 / 2021 Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
Copenhagen, DK and Boston, MA, U.S. November 19, 2021 - Zealand Pharma A/S... |
| 19.11.2021 | Zealand Pharma increases its share capital as a consequence of exercise of employee warrants | Company announcement – No. 69/ 2021
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
Copenhagen, DK and Boston, MA, U.S. November 19, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078), a... |
| 12.11.2021 | Zealand Pharma Presents Financial Results for the First Nine Months of 2021; Provides Updates on Commercial Launch and Timing for Congenital Hyperinsulinism and Short Bowel Syndrome Phase Three Clinic... | Zealand Pharma Presents Financial Results for the First Nine Months of 2021; Provides Updates on Commercial Launch and Timing for Congenital Hyperinsulinism and Short Bowel Syndrome Phase Three Clinical Studies
Copenhagen, DK and Boston, MA... |
| 12.11.2021 | Zealand Pharma to Participate in Jefferies London Healthcare Conference | Company announcement – No. 68 / 2021
Zealand Pharma to Participate in Jefferies London Healthcare Conference
Copenhagen, DK and Boston, MA, U.S. November 12, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 20045078,) a biotechnology compa... |
| 11.11.2021 | Zealand Pharma Presents Financial Results for the First Nine Months of 2021; Provides Updates on Commercial Launch and Timing for Congenital Hyperinsulinism and Short Bowel Syndrome Phase Three Clinic... | Company announcement – No. 67/ 2021
Interim report for 9M 2021
Zealand Pharma Presents Financial Results for the First Nine Months of 2021; Provides Updates on Commercial Launch and Timing for Congenital Hyperinsulinism and Short Bowel Synd... |
| 11.11.2021 | Zealand Pharma Presents Financial Results for the First Nine Months of 2021; Provides Updates on Commercial Launch and Timing for Congenital Hyperinsulinism and Short Bowel Syndrome Phase Three Clinic... | Company announcement – No. 67/ 2021
Interim report for 9M 2021
Zealand Pharma Presents Financial Results for the First Nine Months of 2021; Provides Updates on Commercial Launch and Timing for Congenital Hyperinsulinism and Short Bowel Synd... |
| 04.11.2021 | Zealand Pharma Announces First Subject Dosed in Phase 1 Trial of Amylin Analogue ZP8396 for the Treatment of Obesity | Company announcement – No. 65/ 2021
Zealand Pharma Announces First Subject Dosed in Phase 1 Trial of Amylin Analogue ZP8396 for the Treatment of Obesity
Preclinical data have shown potent anti-obesity effects of ZP8396 both as a monotherapy... |
| 04.11.2021 | Zealand Pharma Hosts Conference Call on November 11 at 4 pm CET (10 am ET) to Present Third Quarter Results for 2021 | Company announcement – No. 64 / 2021
Zealand Pharma Hosts Conference Call on November 11 at 4 pm CET (10 am ET) to Present Third Quarter Results for 2021
Copenhagen, DK and Boston, MA, U.S. November 4, 2021 – Zealand Pharma A/S (Nasdaq: ZEA... |
| 01.11.2021 | Zealand Pharma Announces Presentation of Preclinical Data on Amylin Analogue, ZP8396, and Clinical Data on Glucagon-GLP1 Dual-Agonist, BI 456906, at The Obesity Society Annual Meeting | Company announcement – No. 63 / 2021
Zealand Pharma Announces Presentation of Preclinical Data on Amylin Analogue, ZP8396, and Clinical Data on Glucagon-GLP1 Dual-Agonist, BI 456906, at The Obesity Society Annual Meeting Preclinical data sh... |
| 01.11.2021 | Zealand Pharma Announces Presentation of Preclinical Data on Amylin Analogue, ZP8396, and Clinical Data on Glucagon-GLP1 Dual-Agonist, BI 456906, at The Obesity Society Annual Meeting | Company announcement – No. 63 / 2021
Zealand Pharma Announces Presentation of Preclinical Data on Amylin Analogue, ZP8396, and Clinical Data on Glucagon-GLP1 Dual-Agonist, BI 456906, at The Obesity Society Annual Meeting Preclinical data sh... |
| 19.08.2021 | Zealand Pharma Announces First Patient Dosed in EASE-SBS 4 Phase 3b Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome | Company announcement – No. 52 / 2021
Zealand Pharma Announces First Patient Dosed in EASE-SBS 4 Phase 3b Trial Assessing Glepaglutide in Patients with Short Bowel Syndrome
The EASE-SBS 4 Phase 3b trial will evaluate long-term effect on inte... |
| 12.08.2021 | Zealand Pharma Launches ZEGALOGUE® (dasiglucagon) Injection and Advances Pipeline Programs Across Multiple Therapeutic Areas | Company annoucement - No. 50 / 2021
Interim report for H1 2021
Zealand Pharma Launches ZEGALOGUE® (dasiglucagon) Injection and Advances Pipeline Programs Across Multiple Therapeutic Areas
Copenhagen, DK and Boston, MA, U.S. August 12, 2021 ... |
| 24.06.2021 | Zealand Pharma Announces U.S. Commercial Availability of ZEGALOGUE® (dasiglucagon) injection | Company announcement – No. 41/ 2021
Zealand Pharma Announces U.S. Commercial Availability of ZEGALOGUE® (dasiglucagon) injection ZEGALOGUE now available in both an auto-injector and prefilled syringe for the treatment of severe hypoglycemia... |
| 16.06.2021 | ZEALAND PHARMA A/S
Zealand Pharma to Present Data on Glucagon Analog, Dasiglucagon, at the 81st Annual American Diabetes Association Scientific Sessions | Company announcement – No. 39/2021
Zealand Pharma to Present Data on Glucagon Analog, Dasiglucagon, at the 81st Annual American Diabetes Association Scientific Sessions
Company to present six abstracts on ZEGALOGUE® (dasiglucagon) injection... |
| 02.06.2021 | ZEALAND PHARMA A/S
Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH | Company announcement – No. 35/ 2021
Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH FDA’s Fast Track Designation for the GLP-1/glucagon dual agonist underscores the urgent ne... |
| 01.06.2021 | Minutes from the Extraordinary General Meeting in Curasight A/S | Minutes from the Extraordinary General Meeting in Curasight A/S Tue, Jun 01, 2021 12:01 CET
Curasight A/S, CVR no. 35 24 93 89 (“Curasight” or the “Company”) held an extraordinary general meeting on 1 June 2021 at 11:00 (CET). Due to the CO... |
| 27.05.2021 | ZEALAND PHARMA A/S
Zealand Pharma A/S : launches long-term incentive program for Zealand's US based Corporate Management for 2021 | Company announcement – No. 33 / 2021
Zealand Pharma launches long-term incentive program for Zealand’s US based Corporate Management for 2021
Copenhagen, DK and Boston, MA, U.S., May 27, 2021 – Zealand Pharma A/S (“Zealand”) (NASDAQ: ZEAL) ... |
| 18.05.2021 | Notice of Extraordinary General Meeting | Notice of Extraordinary General Meeting Tue, May 18, 2021 13:00 CET
Copenhagen, Denmark, 18 May 2021 – Notice is hereby given of an extraordinary general meeting of Curasight A/S to be held on:
Tuesday, 1 June 2021 at 11:00 am CET
Due to th... |
| 12.05.2021 | ZEALAND PHARMA A/S
Zealand Pharma A/S : launches long-term incentive program for Zealand's Executive Management and employees for 2021 | Company announcement – No. 28/ 2021
Zealand Pharma launches long-term incentive program for Zealand’s Executive Management and employees for 2021
Copenhagen, DK and Boston, MA, U.S. May 5, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 2... |
| 29.04.2021 | ZEALAND PHARMA A/S
Zealand Pharma A/S : launches long-term incentive program for Zealand's Board of Directors and grants for 2021 | Company announcement – No. 23 / 2021
Zealand Pharma launches long-term incentive program for Zealand’s Board of Directors and grants for 2021
Copenhagen, DK and Boston, MA, U.S., April 29, 2021 – Zealand Pharma A/S (Nasdaq: ZEAL) (CVR-no. 2... |
| 10.08.2017 | Zealand bags a $77M IPO haul as investors embrace another biotech offering | Copenhagen-based Zealand Pharma is the latest biotech to march out onto Nasdaq this year. The peptide drug developer — closely allied with Sanofi — raised $77 million after selling an upsized package of 4.4 million shares a... |
| 09.08.2017 | Term Sheet — Wednesday, Aug. 9 | ET CETERA
Good morning! I’m attending to some magazine duties today, so here’s some news from my Fortune colleagues:
Paid Content What you need to know about growing cyberattacks From ExtraHop
The event itself was elaborate. After arriving ... |
| 03.08.2017 | Term Sheet — Thursday, Aug. 3 | MARKDOWNS AGAIN
After we wrote about mutual fund markdowns to Uber’s share price, a few readers wrote in asking how mutual funds determine their markdowns.
Paid Content What you need to know about growing cyberattacks From ExtraHop
• This i... |
| 07.07.2017 | Zealand Pharma blueprints an $86M IPO on Nasdaq as it maneuvers its way into PhIII | Copenhagen-based Zealand Pharma is following a clearly blazed trail from Europe to Nasdaq in search of an IPO that can help fund a pair of late-stage drugs.
Following the upbeat results for AC Immune (Switzerland) $ACIU and Ar... |
